Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study.
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inadequate antimicrobial treatment is an independent determinant of hospital mortality, and fungal bloodstream infections are among the types of infection with the highest rates of inappropriate initial treatment. Because of significant potential for reducing high mortality rates, we sought to assess the impact of delayed treatment across multiple study sites. The goals our analyses were to establish the frequency and duration of delayed antifungal treatment and to evaluate the relationship between treatment delay and mortality. METHODS: We conducted a retrospective cohort study of patients with candidemia from 4 medical centers who were prescribed fluconazole. Time to initiation of fluconazole therapy was calculated by subtracting the date on which fluconazole therapy was initiated from the culture date of the first blood sample positive for yeast. RESULTS: A total of 230 patients (51% male; mean age +/- standard deviation, 56 +/- 17 years) were identified; 192 of these had not been given prior treatment with fluconazole. Patients most commonly had nonsurgical hospital admission (162 patients [70%]) with a central line catheter (193 [84%]), diabetes (68 [30%]), or cancer (54 [24%]). Candida species causing infection included Candida albicans (129 patients [56%]), Candida glabrata (38 [16%]), Candida parapsilosis (25 [11%]), or Candida tropicalis (15 [7%]). The number of days to the initiation of antifungal treatment was 0 (92 patients [40%]), 1 (38 [17%]), 2 (33 [14%]) or > or = 3 (29 [12%]). Mortality rates were lowest for patients who began therapy on day 0 (14 patients [15%]) followed by patients who began on day 1 (9 [24%]), day 2 (12 [37%]), or day > or = 3 (12 [41%]) (P = .0009 for trend). Multivariate logistic regression was used to calculate independent predictors of mortality, which include increased time until fluconazole initiation (odds ratio, 1.42; P < .05) and Acute Physiology and Chronic Health Evaluation II score (1-point increments; odds ratio, 1.13; P < .05). CONCLUSION: A delay in the initiation of fluconazole therapy in hospitalized patients with candidemia significantly impacted mortality. New methods to avoid delays in appropriate antifungal therapy, such as rapid diagnostic tests or identification of unique risk factors, are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The mortality reduction associated with early antimicrobials appears strongest in patients with septic shock, where studies have reported a strong association between time to antibiotics and death in patients with septic shock but weaker associations in patients without septic shock (98,109,110).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [109]
In the citing paper
“Blood cultures take an average of 2–3 days to grow Candida, or longer depending on the species.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [135]
In the citing paper
“Attributable mortality from IC remains high and increases with delays in treatment.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [135]
In the citing paper
“Some observational studies suggested that prompt initiation of appropriate empiric antifungal therapy may be associated with a reduction in mortality, however these studies do not prove a causal relationship between antifungal therapy and outcome, nor do they clarify the role of timing of treatment, and some other studies have failed to show this association [167, 171–173].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [171]
In the citing paper
“Multivariate analysis in this study also provided a strong association between delay in therapy and mortality.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [46]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 11×
“By contrast, gram-positive bacteria, such as coagulase-negative staphylococci, S. aureus, and Enterococcus species, account for 60% of all BSIs [16].”
BackgroundInfluentialIbrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779 · cited 2×
“of inappropriate initial treatment [6].”
BackgroundMorrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286 · cited 5×
“Delaying antifungal therapy appears to be a common practice, and the impact on mortality may be significant [8, 10].”
BackgroundResultInfluentialAttributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140 · cited 2×
“Attributable mortality rates of 49% were also shown among patients with candidemia, compared with uninfected control subjects matched for age, sex, date of hospital admission, underlying diseases, length of time at risk, and type of surgical procedure [5].”
BackgroundPfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521 · cited 1×
“[1].”
Morgan, J., Meltzer, M. I., Plikaytis, B. D., Sofair, A. N., Huie-White, S., Wilcox, S., Harrison, L. H., Seaberg, E. C., Hajjeh, R. A., & Teutsch, S. M. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502581 · Cited by 437 · cited 2×
“attributable mortality remains 19%–49% [2, 5].”
Pfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00240-x · Cited by 331 · cited 10×
“By contrast, gram-positive bacteria, such as coagulase-negative staphylococci, S. aureus, and Enterococcus species, account for 60% of all BSIs [16].”
BackgroundInfluentialThe Impact of Candidemia on Length of Hospital Stay, Outcome, and Overall Cost of Illness
Rentz, A. M., Halpern, M. T., & Bowden, R. (1998) · Clinical Infectious Diseases · doi:10.1086/514955 · Cited by 310 · cited 1×
“of 8 cases per 100,000 population [2–4].”
Leinberger, D. M., Schumacher, U., Autenrieth, I. B., & Bachmann, T. T. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.4943-4953.2005 · Cited by 155 · cited 1×
“Development of nonculture methods for the rapid diagnosis of candidemia in patients with BSI may also significantly improve the ability to quickly prescribe appropriate antifungal therapy [19, 20].”
Epidemiology and Prognostic Determinants of Bloodstream Infections in Surgical Intensive Care
Harbarth, S. (2002) · Archives of Surgery · doi:10.1001/archsurg.137.12.1353 · Cited by 135
Cited by
Items 501–600 of 1,000
Current aspects of invasive candidiasis and aspergillosis in adult intensive care patients
Glöckner, A., & Karthaus, M. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01885.x · Cited by 25
New options for treatment of candidaemia in critically ill patients
Ruhnke, M., Härtwig, K., & Kofla, G. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01981.x · Cited by 25
Wu, J., Xie, S., Zhang, G., Zhan, J., Xie, W., Yu, R., Xue, B., Cen, Y., Chai, J., Chen, H., et al. (2014) · Burns & Trauma · doi:10.4103/2321-3868.130182 · Cited by 24
“The usual preventive dose is 400 mg once a day.([65,66]) Voriconazole is sensitive to almost all kinds of Aspergilli, Cryptococcus, Candida including C.”
BackgroundRiddell, J., & Kauffman, C. A. (2008) · Cancer · doi:10.1002/cncr.23465 · Cited by 23
“patients with candidemia is a crucial factor for a successful outcome.(22,23) The selection of initial treatment should be based on factors that include prior antifungal exposure, the clinical status of the patient, and the epidemiology of candidemia at”
BackgroundAll You Need To Know and More about the Diagnosis and Management of Rare Yeast Infections
Sprute, R., Cornely, O. A., Chen, S. C. ‐., Seidel, D., Schuetz, A. N., & Zhang, S. X. (2021) · mBio · doi:10.1128/mbio.01594-21 · Cited by 24
“Timely administration of targeted antifungal therapy is a critical component affecting disease outcomes (32).”
BackgroundVu, C. A., Jimenez, A., Anjan, S., & Abbo, L. M. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13919 · Cited by 23
Garbez, N., Mbatchi, L., Wallis, S. C., Müller, L., Lipman, J., Roberts, J. A., Lefrant, J., & Roger, C. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01062-6 · Cited by 22
Lunel, F. M. V., Donnelly, J. P., van der Lee, H. A. L., Blijlevens, N. M. A., & Verweij, P. E. (2011) · Medical Mycology · doi:10.3109/13693786.2011.582889 · Cited by 23
Non-Invasive Methods to Diagnose Fungal Infections in Pediatric Patients with Hematologic Disorders
Badiee, P., Hashemizadeh, Z., Ramzi, M., Karimi, M., & Mohammadi, R. (2016) · Jundishapur Journal of Microbiology · doi:10.5812/jjm.41573 · Cited by 22
“Some studies focused on pediatric patients with hematological malignancy demonstrated a complete lack of sensitivity of PCR (28); whilst in others sensitivities were similar to those of the current population (8).”
BackgroundResultNieto, M., Robles, J. C., Causse, M., Gutiérrez, L., Perez, M. C., Ferrer, R., Xercavins, M., Herrero, E., Sirvent, E., Fernández, C., et al. (2019) · Infectious Diseases and Therapy · doi:10.1007/s40121-019-0248-z · Cited by 24
A seven-year surveillance of Candida bloodstream infection at a university hospital in KSA
Al-Musawi, T. S., Alkhalifa, W., Alasaker, N. A., Rahman, J. U., & Alnimr, A. M. (2020) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2020.12.002 · Cited by 24
“found that a delay of each day to initiate effective antifungal therapy, from day 1 to day 4 or more, increased the mortality in candidemia cases in an ascending manner prospectively to 15%, 24%, 37%, and 41%.(30) Although the present study was not designed to assess the timing for initiating appropriate antifungal tr…”
Díez, A., Carrano, G., Bregón-Villahoz, M., Cuétara, M. S., García‐Ruiz, J. C., Fernandez-de-Larrinoa, Í., & Moragues, M. D. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115509 · Cited by 25
Present situation in the treatment of invasive fungal infection
Pauw, B. E. D., & Picazo, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70020-7 · Cited by 25
Recent advances in the treatment of life-threatening, invasive fungal infections
Drew, R. H., Townsend, M. L., Pound, M. W., Johnson, S. W., & Perfect, J. R. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.838217 · Cited by 31
“Prompt use of appropriate antifungals in the treatment of IFIs has been associated with a decrease in mortality in patients with IFIs, notably IC [15-17] and zygomycosis [18].”
BackgroundTreatment of invasive candidiasis with echinocandins
Glöckner, A., Steinbach, A., Vehreschild, J. J., & Cornely, O. A. (2009) · Mycoses · doi:10.1111/j.1439-0507.2008.01645.x · Cited by 23
McKeating, C., White, P. L., Posso, R. B., Palmer, M., Johnson, E. M., & McMullan, R. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2017-204692 · Cited by 22
Κey Role of Early Source Control in Candidemic Patients With Sepsis or Septic Shock
Papadimitriou‐Olivgeris, M., Battistolo, J., Poissy, J., Coste, A. T., Bochud, P., Calandra, T., Senn, L., & Lamoth, F. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac383 · Cited by 21
Elalouf, A., Elalouf, H., & Rosenfeld, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292625 · Cited by 24
Anidulafungin for the treatment of invasive candidiasis
Mayr, A., Aigner, M., & Lass‐Flörl, C. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03448.x · Cited by 25
Prospective observational multicenter study to define a diagnostic algorithm for biliary candidiasis
Lenz, P., Eckelskemper, F., Erichsen, T. J., Lankisch, T. O., Dechêne, A., Lubritz, G., Lenze, F., Beyna, T., Ullerich, H., Schmedt, A., et al. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.12260 · Cited by 25
Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes
Ruan, S., Huang, Y., Chu, C.-C., Yu, C., & Hsueh, P. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.02.021 · Cited by 22
Dupont, H., Mahjoub, Y., Chouaki, T., Lorne, E., & Zogheib, E. H. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002698 · Cited by 22
Hartl, B., Zeller, I., Manhart, A., Selitsch, B., Lass‐Flörl, C., & Willinger, B. (2018) · Mycopathologia · doi:10.1007/s11046-017-0238-1 · Cited by 22
Pietrobom, P. M. P., & Colombo, A. L. (2020) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000684 · Cited by 22
Typing of Candida isolates from patients with invasive infection and concomitant colonization
Brillowska-Dabrowska, A., Bergmann, O., Jensen, I. M., Jarløv, J. O., & Arendrup, M. C. (2010) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365540903348336 · Cited by 21
Glöckner, A., & Cornely, O. A. (2012) · Mycoses · doi:10.1111/j.1439-0507.2012.02208.x · Cited by 21
Treatment of Invasive Candidiasis in Immunocompromised Pediatric Patients
Fisher, B. T., & Zaoutis, T. E. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810050-00003 · Cited by 22
Hof, H. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01522.x · Cited by 22
Estrada-Barraza, D., Martínez, A. D., Flores-Padilla, L., Elias, R. M.-D., & Sánchez-Vargas, L. O. (2010) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2010.11.003 · Cited by 20
The Diagnostic and Therapeutic Approach to Fungal Infections in Critical Care Settings
Zaragoza, R., & Pemán, J. (2008) · Cited by 21
Graus, M. S., Neumann, A. K., & Timlin, J. A. (2017) · Journal of Biomedical Optics · doi:10.1117/1.jbo.22.1.016002 · Cited by 21
Reuken, P. A., Kruis, W., Maaser, C., Teich, N., Büning, J., Preiß, J., Schmelz, R., Bruns, T., Fichtner‐Feigl, S., Stallmach, A., et al. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy017 · Cited by 22
T2Candida magnetic resonance in patients with invasive candidiasis: Strengths and limitations
Zurl, C., Prattes, J., Zollner‐Schwetz, I., Valentin, T., Rabensteiner, J., Wunsch, S., Hoenigl, M., & Krause, R. (2019) · Medical Mycology · doi:10.1093/mmy/myz101 · Cited by 23
Klingspor, L., Muhammed, S. A., & Özenci, V. (2012) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-012-1650-6 · Cited by 20
Laakso, S., Kirveskari, J., Tissari, P., & Mäki, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026655 · Cited by 20
“Time to diagnosis for sepsis and an early initiation of effective antimicrobial therapy has been a major predictor of an outcome of a septic patient [2,3,4].”
BackgroundMaldonado, N. A., Cano, L. E., de BEDOUT, C., Arbeláez, C. A. R., Roncancio, G. E., Tabares, A., Robledo, C. G., & Robledo, J. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.02.003 · Cited by 24
“Early initiation of appropriate antifungal therapy in patients with invasive Candida infections is essential for reducing morbidity and mortality rates (Garey et al., 2006).”
BackgroundThe Role of PET in Monitoring Therapy in Fungal Infections
Ankrah, A. O., Klein, H. C., Span, L. F. R., de Vries, E. F. J., Dierckx, R., Sathekge, M. M., & Glaudemans, A. W. J. M. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612824666171213101648 · Cited by 20
“A delay in therapy institution in IFIs is associated with increased mortality [56-59].”
BackgroundEfficacy of caspofungin in invasive candidiasis and candidemia – de‐escalation strategy
Lichtenstern, C., Nguyen, T. H., Schemmer, P., Hoppe‐Tichy, T., & Weigand, M. A. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01527.x · Cited by 20
The challenges of the genome-based identification of antifungal resistance in the clinical routine
Alastruey‐Izquierdo, A., & Martín-Galiano, A. J. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1134755 · Cited by 20
“Besides, they are labor-intensive and time-consuming which has a direct impact in mortality (Garey et al., 2006; Chamilos et al., 2008).”
BackgroundSerum (1,3)-beta-D-glucan is an inefficient marker of breakthrough candidemia
Abe, M., Kimura, M., Araoka, H., Taniguchi, S., & Yoneyama, A. (2014) · Medical Mycology · doi:10.1093/mmy/myu066 · Cited by 19
“Candidemia was associated with high morbidity and mortality, and early initiation of antifungal therapy in patients with invasive candidiasis has been demonstrated to be crucial to reduce mortality [14,15].”
BackgroundTimsit, J., Azoulay, É., Cornet, M., Gangneux, J., Jullien, V., Vesin, A., Schir, É., & Wolff, M. (2013) · Trials · doi:10.1186/1745-6215-14-399 · Cited by 21
“reported in patients with candidemia [14-17].”
Pemán, J., & Zaragoza, R. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.128 · Cited by 21
A Risk Score for Fluconazole Failure among Patients with Candidemia
Ostrosky-Zeichner, L. L., Harrington, R. L., Azie, N. E., Yang, H., Li, N., Zhao, J., Koo, V., & Wu, E. Q. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02091-16 · Cited by 19
“by 50% with an antifungal therapy initiation delay of just 1 day from the onset of symptoms (19).”
BackgroundEscribano, P., Marcos-Zambrano, L. J., Gómez, A., Sánchez, C., Martínez‐Jiménez, M. D. C., Bouza, E., & Guinea, J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00400-17 · Cited by 19
Almoosa, Z., Ahmed, G. Y., Omran, A., AlSarheed, A. S., Alturki, A., Alaqeel, A., Alshehri, M., AlFawaz, T. S., & AlShahrani, D. A. (2017) · Saudi Medical Journal · doi:10.15537/smj.2017.11.21116 · Cited by 20
Jones, T. M., Drew, R. H., Wilson, D. T., Sarubbi, C., & Anderson, D. J. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp170113 · Cited by 20
“We did not include the time of positive Gram’s stain notifications and the time of interventions made by ASP personnel, which have been used in previous studies.(12-18,21) We also excluded patients receiving appropriate therapy for more than 48 hours before the qualifying blood culture draw, which may have limited the…”
BackgroundMethodInfluentialBailly, S., Gautier‐Veyret, E., Lê, M., Bouadma, L., Andremont, O., Neuville, M., Mourvillier, B., Sonneville, R., Magalhaes, É., Lebut, J., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01545-20 · Cited by 19
Epidemiology of Candidemia in Children over 7 Years in a Medical Center in Turkey
Çiftdoğan, D. Y., Aksay, A. K., Erbaş, G., Sarkış, Ü. B., Öncel, E. K., Anıl, A. B., Baran, M., Er, H., & Yılmaz, N. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00453-21 · Cited by 20
New nonculture-based methods for the diagnosis of invasive candidiasis
Billé, J. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e04df · Cited by 20
Recognition and prevention of nosocomial invasive fungal infections in the intensive care unit
Smith, J. A., & Kauffman, C. A. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181e6cf25 · Cited by 20
“If therapy is delayed for 48 hrs after the culture is taken, waiting until the culture results are known, mortality seems to increase (37, 38).”
Background1,3-ß-d-Glucan testing is highly specific in patients undergoing dialysis treatment
Prattes, J., Schneditz, D., Prüller, F., Jaindl, E., Sauseng, N., Hoenigl, M., Schilcher, G., & Krause, R. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.09.005 · Cited by 20
Torosantucci, A., Tumbarello, M., Bromuro, C., Chiani, P., Posteraro, B., Sanguinetti, M., Cauda, R., & Cassone, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-02977-6 · Cited by 20
Fidler, G., Leiter, É., Kocsubé́, S., Bíró, S., & Paholcsek, M. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3283-6 · Cited by 19
Zhang, M., Rao, Z.-G., Ma, T., Tang, M., Xu, T., He, X.-X., Li, Z.-P., Liu, Y., Xu, Q.-J., Yang, K., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.952611 · Cited by 19
Miyazaki, T., & Kohno, S. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1058157 · Cited by 20
Holzknecht, B. J., Thorup, J. M., Arendrup, M. C., Andersen, S. E., Steensen, M., Hesselfeldt, P., Nielsen, J., & Knudsen, J. D. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03422.x · Cited by 19
Dudiuk, C., Gamarra, S. P., Jiménez‐Ortigosa, C., Leonardelli, F., Macedo, D., Perlin, D. S., & García‐Effrón, G. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00398-15 · Cited by 23
“It is well understood that rapid initiation of appropriate antifungal therapy reduces candidemia mortality rates (26, 27).”
BackgroundLee, I., Morales, K. H., Zaoutis, T. E., Fishman, N. O., Nachamkin, I., & Lautenbach, E. (2010) · American Journal of Infection Control · doi:10.1016/j.ajic.2010.02.016 · Cited by 18
Park, H. J., Park, M., Han, M., Nam, B., Koh, K., Im, H. J., Lee, J. W., Chung, N.-G., Cho, B., Kim, H.-K., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.136 · Cited by 18
Pappas, P. G., Kauffman, C. A., Andes, D. R., Benjamin, D. K., Calandra, T., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B. J., Ostrosky-Zeichner, L. L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598961 · Cited by 26
“La identificación de pacientes en riesgo de contraer infecciones por Candida y el pronto inicio de la terapia antifúngica son fundamentales [77, 78].”
BackgroundGodoy, J. S. R., Kioshima, É. S., Abadio, A. K. R., Felipe, M. S. S., de Freitas, S. M., & Svidzinski, T. I. E. (2015) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-7223-8 · Cited by 18
Snydman, D. R. (2007) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70047-6 · Cited by 18
Villalobos, J. M., Castro, J. A., Montoya, A. A. A., Peláez, M. C., Somogyi, T., & Sandoval, L. (2016) · Revista chilena de infectología · doi:10.4067/s0716-10182016000200005 · Cited by 25
Knabl, L., & Lass‐Flörl, C. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1760841 · Cited by 22
Otto, C. C., & Babady, N. E. (2023) · Mycopathologia · doi:10.1007/s11046-023-00765-7 · Cited by 18
MartÃnez, J. M. G., mez, E. V. G., Pemán, J., n, E. C., GarcÃa, M. G. M., & Agudo, L. D. C. (2009) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2009.04595.x · Cited by 18
“…and accurate diagnosis of an invasive fungal infection is critical for early and appropriate treatment because patient prognosis improves if diagnosis is established early in invasive fungal infection, and adequate antifungal treatment is initiated sooner (Karp et al. 1991; Garey et al. 2006).”
BackgroundGuo, Y., Yang, J.-X., & Liang, G. (2015) · Mycopathologia · doi:10.1007/s11046-015-9977-z · Cited by 19
Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia
Arendrup, M. C., Cuenca‐Estrella, M., Donnelly, J. P., Lass‐Flörl, C., & Rodríguez-Tudela, J. L. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01411-08 · Cited by 18
Francisco, E. C., Cáceres, D. H., Brunelli, J. G. P., García‐Effrón, G., Arastehfar, A. A., Ribeiro, F. D. C., Almeida, M. N. D., Gonçalves, S. S., de Almeida, J. N., Lass‐Flörl, C., et al. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00064-23 · Cited by 18
Zheng, S., Ng, T. Y., Li, H., Tan, A. L., Tan, T. T., & Tan, B. H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164668 · Cited by 19
Hoenigl, M., Enoch, D., Wichmann, D., Wyncoll, D. L. A., & Cortegiani, A. (2024) · Mycopathologia · doi:10.1007/s11046-024-00852-3 · Cited by 17
“Additionally, treatment delay in IC infections is a major factor predicting mortality [32, 33], as echoed in the 90% agreement of respondents in this study.”
Bailly, S., Leroy, O., Azoulay, É., Montravers, P., Constantin, J., Dupont, H., Guillemot, D., Lortholary, O., Mira, J. P., Pérrigault, P.-F., et al. (2017) · Journal of Infection · doi:10.1016/j.jinf.2016.12.016 · Cited by 17
Klingspor, L., Lindbäck, E., Ullberg, M., & Özenci, V. (2017) · Mycoses · doi:10.1111/myc.12722 · Cited by 19
Tarai, B., Jain, D. K., Das, P., & Budhiraja, S. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3188-8 · Cited by 18
“Starting effective antibiotic treatment as early as possible, following early identification of pathogens, significantly impacts the disease outcome [2, 3].”
BackgroundInfluentialCandidemia in the patient with malignancy
Alves, J., Palma, P., Azevedo, D., & Rello, J. (2018) · Hospital Practice · doi:10.1080/21548331.2018.1508290 · Cited by 19
“Administration of appropriate and timely antifungal treatment is an independent factor associated with reduced mortality [10,24,46,47].”
BackgroundBordallo-Cardona, M. Á., Sánchez‐Carrillo, C., Muñóz, P., Bouza, E., Escribano, P., & Guinea, J. (2018) · Medical Mycology · doi:10.1093/mmy/myy097 · Cited by 17
da Silva, A. M. P. D. S., de Moraes‐Pinto, M. I., Pignati, L. T., Teixeira, B. B., Lima, A. P. C., Germano, P. C. P., Petrilli, A. S., Marques, L. M. A., & Carlesse, F. A. D. M. C. (2020) · Mycoses · doi:10.1111/myc.13106 · Cited by 19
Antibiotic treatment in patients with sepsis: a narrative review
Plata-Menchaca, E. P., Ferrer, R., Ruiz‐Rodríguez, J. C., Morais, R., & Póvoa, P. M. S. R. (2020) · Hospital Practice · doi:10.1080/21548331.2020.1791541 · Cited by 17
Sakamoto, Y., Kawabe, K., Suzuki, T., Sano, K., Ide, K., Nishigaki, T., Enoki, Y., Taguchi, K., Koike, H., Kato, H., et al. (2021) · Journal of Fungi · doi:10.3390/jof7080596 · Cited by 17
“Therefore, adequately treating candidemia is critical for improving patient prognosis [7,8].”
BackgroundMalý, J., Szárszoi, O., Netuka, I., Dorazilová, Z., & Pirk, J. (2013) · Journal of Cardiac Surgery · doi:10.1111/jocs.12258 · Cited by 17
“was delayed.(40,41)We do not have robust data regarding post-transplant survival in patients whowere bridged to transplant with circulatory support devices and developed fungal infections before transplant.”
BackgroundResultDirect fluconazole susceptibility testing of positive Candida blood cultures by flow cytometry
Rudensky, B., Broide, E., Berko, N., Weil‐Weiner, Y., Yinnon, A. M., & Raveh, D. (2007) · Mycoses · doi:10.1111/j.1439-0507.2007.01466.x · Cited by 19
Sepsis: A Review for the Neurohospitalist
Karnatovskaia, L. V., & Festić, E. (2012) · The Neurohospitalist · doi:10.1177/1941874412453338 · Cited by 24
“In a study by Garey et al, mortality rates were 15% for patients who received appropriate therapy on day 1 compared with the 41% in those who received antifungal therapy by day 3 or later.(24) Of note, antibiotic use 3 months prior to hospitalization is associated with increased likelihood of developing multidrugresis…”
ResultA Review of Diagnostic Methods for Invasive Fungal Diseases: Challenges and Perspectives
Falci, D. R., Stadnik, C., & Pasqualotto, A. C. (2017) · Infectious Diseases and Therapy · doi:10.1007/s40121-017-0154-1 · Cited by 17
“antifungal therapy on the first day after cultures have an estimated mortality of 24%, increasing to 37% and 41%, respectively, if therapy is started 1 and 2 days later [50, 51].”
BackgroundPCR-based tests for the early diagnosis of sepsis. Where do we stand?
Ginn, A. N., Halliday, C. L., Douglas, A. P., & Chen, S. C. ‐. (2017) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000407 · Cited by 17
Halo Sign and Improved Outcome
Verweij, P. E., van Die, L., & Donnelly, J. P. (2007) · Clinical Infectious Diseases · doi:10.1086/518387 · Cited by 17
Multi‐state evaluation of Candida infections in burn patients
Salimi, M., Javidnia, J., Abastabar, M., Mobayen, M., Moslemi, A., Rahimzadeh, G., Charati, J. Y., Tirabadi, N. M., Nouranibaladezaei, S., Asghari, H., et al. (2024) · Mycoses · doi:10.1111/myc.13788 · Cited by 17
“49,51 Therefore, it is important to know the drug sensitivity pattern before starting treatment with appropri - ate antifungal drugs.”
Bal, A. M., Pana, Z. D., Carlesse, F. A. D. M. C., Marek, A., Seidel, D., Mehler, K., Butzer, S., Sprute, R., Stemler, J., Ludwig-Bettin, D., et al. (2025) · Mycoses · doi:10.1111/myc.70041 · Cited by 16
Why Candida Sepsis Should Matter to ICU Physicians
Skrobik, Y. K., & Laverdière, M. (2013) · Critical Care Clinics · doi:10.1016/j.ccc.2013.06.007 · Cited by 16
van der Geest, P. J., Rijnders, B. J. A., Vonk, A. G., & Groeneveld, A. B. J. (2015) · Mycoses · doi:10.1111/myc.12450 · Cited by 17
Gumbo, T. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ715 · Cited by 16
Zito, A., Bromuro, C., Mandili, G., Chiani, P., Horenstein, A. L., Malavasi, F., Cauda, R., Cassone, A., & Torosantucci, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148714 · Cited by 16
“A main obstacle to an efficient clinical management of invasive candidiasis is the lack of diagnostic methodologies allowing the early detection and treatment of the disease [1–5].”
BackgroundZeng, H., Wu, Z., Yu, B., Wang, B., Wu, C., Wu, J., Lai, J., Gao, X., & Chen, J. (2021) · BMC Cancer · doi:10.1186/s12885-021-07973-8 · Cited by 16
“Background Adult patients who were diagnosed with hematological malignancies, such as acute lymphoblastic leukemia [1], acute myeloid leukemia [2], or myelodysplastic syndrome, and then instructed to receive intensive chemotherapy for remission or hematopoietic stem cell transplantation (HSCT) were at high risk of dev…”
BackgroundFungal Genomics in Respiratory Medicine: What, How and When?
Brackin, A. P., Hemmings, S., Fisher, M. C., & Rhodes, J. L. (2021) · Mycopathologia · doi:10.1007/s11046-021-00573-x · Cited by 16
Hacia el diagnóstico temprano de la candidiasis invasora en el paciente crítico
Pemán, J., & Zaragoza, R. (2012) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2012.03.002 · Cited by 21
Infección fúngica invasiva en los pacientes ingresados en las áreas de críticos
Garnacho‐Montero, J., Díaz‐Martín, A., de Piappon, M. R. P., & García-Cabrera, E. (2012) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2012.02.011 · Cited by 24
Yunus, S., Pieper, S., Kolve, H., Goletz, G., Jürgens, H., & Groll, A. H. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt438 · Cited by 16
Pfaller, M. A. (2015) · Journal of Fungi · doi:10.3390/jof1020217 · Cited by 19
“Savings were predominately due to the shortened hospital stay for survivors and lower hospital costs associated with the lower mortality rates in the T2Candida strategy [40,41].”
BackgroundTratamiento de las infecciones fúngicas en pacientes con neoplasias hematológicas
Mensa, J., de la Cámara, R., Carreras, E., Estrella, M. C., Rodríguez, J. Á. G., Gobernado, M., Picazo, J., Aguado, J. M., & Sanz, M. Á. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2009.01.008 · Cited by 19
Lockhart, S. R., Bolden, C. B., Iqbal, N. J., & Kuykendall, R. J. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05479-11 · Cited by 16
“Early and appropriate antifungal therapy has been shown to have a positive impact on patient outcome and hospitalization costs (1, 10, 15, 20, 31).”
BackgroundAntifungal Susceptibility Testing: A Primer for Clinicians
Kuper, K. M., Coyle, E. A., & Wanger, A. R. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1146 · Cited by 19
“Findings from a multi-institutional retrospective cohort study of 230 patients hospitalized for a minimum of 48 hours who were diagnosed with a first occurrence of candidemia showed that delay in the initiation of fluconazole therapy significantly impacted mortality.(58) In patients who had therapy started on the day…”
Background
Metadata
- Authors
- Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T.
- Affiliations
- University of Houston (US)
- University of New Mexico (US)
- Baptist Memorial Health Care (US)
- University of Tennessee Health Science Center (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Oregon State University (US)
- Corresponding author
- Garey, Kevin W.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-07
- Volume
- 43
- Issue
- 1
- Pages
- 25-31
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2164001967
- Semantic Scholar
- e1a67fd5e540307550577ea7a071370b075e943f
- Cited by
- 1,171
- References
- 20
- Citations by year
- 2026: 31 · 2025: 26 · 2024: 31 · 2023: 31 · 2022: 49 · 2021: 67 · 2020: 51 · 2019: 51 · 2018: 62 · 2017: 66 · 2016: 61 · 2015: 74 · 2014: 87 · 2013: 83 · 2012: 77
- FWCI
- 35.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Enzon Pharmaceuticals
- University of Houston
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, fluconazole, treatment delay, mortality, fungemia, Candida albicans, APACHE II score, mortality risk factors, hospitalized patients, Candida tropicalis, Candida parapsilosis, Candida glabrata, diabetes mellitus, cancer patients, sepsis
- MeSH terms
- Adult, Aged, Antifungal Agents, Candidiasis, Female, Humans, Length of Stay, Male, Middle Aged, Retrospective Studies, Time Factors, Cohort Studies, Fluconazole, Fungemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.